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Abstract 
Background: Although a few case reports about hypertensive anaphylaxis (HA) are available in the present literature, 
there is no study about the prevalence of HA. In this study, we review our cases with anaphylaxis presenting with 
hypertension and ascertain its prevalence. The documents of the patients who had anaphylactic reactions after the 
procedures performed for the diagnosis and treatment of allergic diseases in GATA Haydarpasa Clinic of Allergy and 
Immunology between January 2010 and December 2014 were retrospectively reviewed. Within the study period, 324 
patients had undergone 4332 procedures in which 62 of them had developed anaphylaxis.
Results: During the procedures, the rate of anaphylaxis was found to be 1.43 %. The rate of HA among the anaphy-
laxis patients was 12.9 % (8 of 62 patients). During treatments, 2 patients received adrenaline injections without any 
adverse reaction.
Conclusions: HA may be seen at a considerable rate during an anaphylactic reaction. Anaphylaxis and hypertension 
can be recovered by adrenaline injection when required. According to the best of our knowledge, this study is the 
first original study about the prevalence of HA in English-language medical literature.
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Background
Anaphylaxis is an acute, potentially life-threatening sys-
temic allergic reaction which has a particular importance 
to all health-care professionals. Diagnosis of anaphylaxis 
is usually based on the history of allergen exposure and 
physical findings (Sampson et al. 2006; Simons 2010).
Anaphylactic reactions like airway, breathing and cir-
culatory problems are not always associated with skin 
and mucosal changes. Other than the upper airway 
obstruction, cardiovascular collapse is the second most 
life-threatening anaphylactic reaction which requires an 
urgent treatment. Reduced blood pressure after exposure 
is known to be the leading indicator of anaphylactic reac-
tion (Muraro et al. 2014).
Hypotension is the most common cardiovascular sys-
tem finding and considered to be a criterion for diagnosis 
of anaphylaxis. Nonetheless, we hypothesize that hyper-
tension can also be encountered in anaphylactic reactions 
due to compensatory vasopressor responses. Although 
there are a few case reports in literature, no study about 
the prevalence of hypertensive anaphylaxis (HA) has 
been reported. In this study, we analyzed our cases with 
anaphylaxis who presented with hypertension in order to 
ascertain the prevalence of HA.
Methods
The documents of the patients who had anaphylactic 
reactions after the procedures performed for the diagno-
sis and treatment of allergic diseases in GATA Haydar-
pasa Clinic of Allergy and Immunology between January 
2010 and December 2014 were retrospectively reviewed. 
The procedures causing anaphylactic reactions were 
allergen immunotherapy, allergy provocation tests (medi-
cation, food, physical urticaria, exercises) and allergic 
skin tests.
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Before all the procedures, a follow-up form has been 
created.  Information about medical histories of the 
patients were obtained, vital signs were measured and 
recorded to the follow-up form.  First blood pressure 
value measured was regarded as the basal blood pres-
sure. Patient’s blood pressure was recorded and evalu-
ated according to the instructions mentioned in Eighth 
Joint National Committee Guideline (James et al. 2013). 
Patients who had been previously diagnosed with hyper-
tension, treated for hypertension or measured hyper-
tensive as basal blood pressure were excluded from the 
study. Patients with any previous diagnosis of multiple 
drug intolerance syndrome, neuropsychiatric diseases 
(anxiety, panic disorder, psychogenic dyspnea, disso-
ciative disorder, globus hystericus, conversion) were also 
excluded from the study. Clinical criteria for diagnosing 
anaphylaxis were based on The European Academy of 
Allergy and Clinical Immunology (EAACI) 2014 Guide-
line (Muraro et  al. 2014). Following initial symptoms of 
anaphylaxis, patients those with the arterial tension of 
over 140/90 mmHg were considered to have a hyperten-
sive anaphylactic reaction (James et al. 2013).
For patients who were interfered with the diagnosis of 
hypertensive anaphylactic reaction, the factors causing 
anaphylactic reaction, symptoms, arterial blood pressure 
(BP) measurements and the treatments performed were 
all noted and evaluated. After the symptoms decreased, 
the patients were kept under observation, vital signs were 
monitored hourly for 6 h.
The local ethics committee approved the study proto-
col and written informed consent was obtained from all 
participants.
Results
Within the study period, 324 patients had undergone 
4332 procedures in which 62 of them had developed 
anaphylaxis. During these procedures, the rate of ana-
phylaxis was found to be 1.43  %. Eight patients with 
HA fitted the criteria mentioned above (4 females, 4 
males). The rate of HA among the anaphylaxis patients 
was 12.9 % (Table 1). The mean age of HA patients was 
25.8  years. Among HA patients, two had anaphylactic 
reaction following bee venom administration (1 patient 
received vespula venom, 1 patient received Apis mel-
lifera therapy), one had anaphylactic reaction following 
fresh prick test with multi-foods, four had anaphylaxis 
following house dust mite (HDM) mixture administra-
tion, and one had anaphylactic reaction after the applica-
tion of omalizumab (Table 2). Reactions developed in the 
course of the increasing dose application in 1 patient who 
received a bee venom immunotherapy and in 2 patients 
who received a HDM immunotherapy.
Following the HA reaction, and just before the initia-
tion of anaphylaxis treatment, the systolic and diastolic 
BPs were measured, and were expected to be between 
150 and 220  mmHg versus 90 and 150  mmHg, respec-
tively, to be considered as HA. During treatment, 2 
patients received epinephrine injections (one had addi-
tional nebulized epinephrine) without any complication. 
The BPs of patients who had received epinephrine were 
150/90 and 150/100 mmHg, respectively. The symptoms 
of all patients recovered within minutes (1–10 min) fol-
lowing treatments.
We performed a 4-day-rush protocol on 2 of our 
patients (patients numbered 1 and 2) who had devel-
oped an anaphylaxis due to venom immunotherapy. One 
of these patients had developed a monthly maintenance 
level, while the other one had an initial build-up phase 
anaphylaxis. One patient who had received an immuno-
therapy due to HDM had a monthly maintenance level, 
whereas two patients had developed an initial build-up 
phase anaphylaxis (patients numbered 4, 5 and 6). Three 
of the patients who had anaphylaxis during the immu-
notherapy had also developed papular urticarial lesions 
during reaction (patients numbered 1, 6, and 7).
One patient (patient numbered 8) who had been 
diagnosed with multiple drug, food and latex allergy 
and receiving omalizumab injections for chronic urti-
caria and angioedema had anaphylactic reaction in 2nd 
year of treatment. Upon the start of this patient’s com-
plaints, 0.5  mg of subcutaneous epinephrine and nebu-
lized epinephrine was administered. Following this 
Table 1 Patients tested or treated for allergy and prevalence of anaphylaxis












Bee-venom 33 25 569 15/569 (2.63) 2/15 (13.33)
Food-drug provocation test 42 36 101 32/101 (3.12) 1/32 (3.12)
Inhalen Allergen IT (immuno-
therapy)
27.7 177 3194 14/3194 (0.43) 4/14 (28.57)
Drug Injection (Omalizumab) 44 86 468 1/468 (0.21) 1/1 (100)
Total 36 324 4332 62/4332 (1.43) 8/62 (12.90)
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procedure, arterial BP was increased to 180/100 from 
150/100 mmHg. Since the increased complaints indicat-
ing an upper airway obstruction, intramuscular 0.3  mg 
epinephrine was also administered. Then, the complaints 
resolved and high BP was normalized. The patient had 
received this treatment several times without expe-
riencing any allergic reaction until the occurrence of 
anaphylaxis.
One patient (patient numbered 3) who was thought to 
have multiple food allergies, developed HA during fresh 
prick testing (prick to prick). This patient had a medical 
history of anaphylactic reactions (common body rash 
and erythema, swelling of the lips, dyspnea) following 
food intake a couple of times. No reaction was observed 
in the skin prick test performed commercially along with 
the ready-made food allergy test panel. On follow-up, 
this patient revealed that he had been experiencing new 
allergic reactions through various fruits which he had 
once eaten without a problem. He stated that he was hav-
ing common rash and erythema on his body along with 
dyspnea after he ate apricot, plums and cherries at dif-
ferent times. He also stated that these complaints were 
accompanied by a blackout, palpitation and sort of a 
coma after he ate peach. A fresh prick testing was per-
formed on the patient by administration of an apricot, 
a peach and a plum. An edema reaction was observed 
which was accompanied by erythemas with the sizes of 
7 × 8 mm, 5 × 6 mm, 6 × 6 mm after peach, apricot and 
plum intake, respectively. Following this test, a severe 
anaphylaxis had developed within 10  min. He was then 
relieved with the administration of antihistaminic, ster-
oid and nebulized bronchodilator therapy.
In patients with hypertensive anaphylactic reaction, the 
blood pressure returned to normal values with regression 
of the other symptoms. Despite the observed improve-
ment, the patients were kept under observation and vital 
signs were monitored hourly for 6 h.
Discussion
Anaphylaxis has an acute and unexpected onset; it may 
vary in severity and may resolve spontaneously. The clini-
cal manifestations of anaphylaxis depend on the organ 
systems involved. Onset of symptoms, clinical severity, 
and sequence of symptom progression varies between 
individuals, and reactions may even vary in the same indi-
vidual between episodes (Järvinen and Celestin 2014). 
Widely accepted criteria to help clinicians identify pos-
sible anaphylaxis emphasize the rapid onset of its multi-
ple symptoms and signs (Sampson et al. 2006). Reduced 
blood pressure after exposure to an allergen (for adults: 
systolic blood pressure of <90 mmHg or >30 % decrease 
from that individual’s baseline) is the leading indicator of 
Table 2 Patients who developed hypertensive anaphylaxis and their managements
M male, F female, ABP arterial blood pressure, HDM house dust mite, ivAH IV antihistaminic, ivSt IV steroid, scE Subcutaneus Epinephrine, imE IM Epinephrine, nBD 
nebulized bronchodilator, nE nebulized epinephrine, ACEi angiotensin converting enzyme inhibitor
a Classical initial anaphylactic symptoms (generalized itching, flushing, swelling of the lips and skin, urticaria) are not mentioned here
b All patients basal blood pressures were normotensive
Case number Sex/age 
(years)








1. M/20 Bee venom allergy Venom immunotherapy 
(vespula 100 mcg)
Papular urticarial  
lesions
170/100 ivAH, ivSt, nBD
2. M/20 Bee venom allergy Venom immunotherapy 
(Apis mellifera 80 mcg)
220/150 ivAH, ivSt, nBD
3. M/20 Anaphylaxis with 
multiple food




190/120 ivAH, ivSt, nBD
4. M/37 Allergic rhinitis Immunotherapy with 
HDM mix (100.000 
SQ-U/ml 0.5 cc)
170/110 ivAH, ivSt, nBD
5. F/19 Asthma and allergic 
rhinitis
Immunotherapy with 
HDM mix (10 IR/ml 
0.2 cc)
Wheezing 150/90 ivAH, imE, nBD
6. F/39 Asthma and allergic 
rhinitis
Immunotherapy with 
HDM mix (10 IR/ml 1 cc)
Papular urticarial  
lesions
150/90 ivAH, ivSt, nBD, ACEi
7. F/29 Asthma and allergic 
rhinitis
Immunotherapy with 
Phostal 350 (1 ml)
Papular urticarial  
lesions
160/100 ivAH, ivSt, nBD, ACEi
8. F/23 Multiple drug, food 





Difficulty in breathing, 
tachycardia
150/100 ivAH, scE, imE, nE, 
ACEi
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an anaphylactic reaction (Muraro et al. 2014). However, 
our results revealed that the prevalence of HA may be at 
a considerable rate (12.90 %), thus, hypotension may not 
be a standard symptom of anaphylactic reaction.
Among other symptoms of anaphylaxis, cutaneous 
manifestations occur in most cases, but it may develop 
without skin changes (Muraro et al. 2014). Respiratory or 
cardiovascular symptoms are the potentially life-threat-
ening features of anaphylaxis (Simons et al. 2012). Respir-
atory symptoms occur more frequently in children, and 
cardiovascular symptoms predominate in adults (Muraro 
et al. 2014). In our cases, respiratory and cardiovascular 
symptoms were more prominent, which may be probably 
due to earlier ages of the patients.
During an anaphylactic reaction, immediate release 
of a series of mediators, including histamines, leukot-
rienes, prostaglandins, thromboxanes, and bradykinins 
from basophils and mast cells cause increased mucous 
membrane secretions, increased capillary permeabil-
ity and leak, markedly reduced smooth muscle tone in 
blood vessels (vasodilation) and bronchioles, and bron-
chial smooth muscle contractions (Ecc Committee S, 
Task Forces of the American Heart A 2005). Internal 
compensatory vasopressor responses such as secretion 
of catecholamines, activation of angiotensin system, pro-
duction of potent vasoconstrictor peptide endothelin-1 
may induce unsteady reactions and in some patients, 
peripheral resistance can increase to abnormally high 
levels during anaphylactic episodes. Serotonin has an 
important role in the mechanism of anaphylaxis which 
may also lead to systemic hypertension over the recep-
tors (serotonin I and serotonin II) (Isbister and Buckley 
2005; Watts 2005).
Epinephrine is a sympathomimetic agent which has an 
effect on vasoconstriction, and bronchodilation. It also 
reduces mucosal edema. Epinephrine down-regulates 
histamine released from mast-cells and other mediators 
of inflammation. It is an optional drug for the treatment 
of anaphylaxis and should be injected promptly in the 
event of an anaphylactic reaction or when progression 
to anaphylaxis is likely to occur (Järvinen and Celestin 
2014).
The differential diagnosis of anaphylaxis includes sev-
eral medical diseases and somatoform disorders, which 
affect the organ systems most frequently involved in 
anaphylaxis (Muraro et al. 2014). Patients having anxiety 
and/or panic disorder had already been excluded from 
this study. No psychiatric pathology had been observed 
in study patients. All of our patients, except for one who 
had immunotherapy, had received their injections sev-
eral times without experiencing any allergic reaction 
before the occurrence of a hypertensive anaphylactic 
reaction.
Allergen immunotherapy has been shown to be an 
effective treatment for respiratory allergies and hyme-
noptera venom allergy. The major risk of an immunother-
apy, especially with the venom, is anaphylaxis, with an 
incidence of up to 12 % for hymenoptera venom (Lockey 
et  al. 1990). It is expected to have more adverse effects 
on ultra-rush (few hours) compared to a rush protocol, 
and with rush compared to cluster protocols. In general, 
although there are commercial preparations used for skin 
tests, in the event that no commercial preparations con-
taining the suspected allergen can be found or that the 
level of the allergen is thought to be quite low, it is pos-
sible to directly perform skin testings by diluting the food 
as it is consumed or through its juice (prick to prick test), 
and in this case, allergic reactions due to the non-stand-
ardized allergen may rarely occur (Bernstein et al. 2008). 
The risk of generalized allergic reactions to skin prick 
testing may be higher in poly-sensitized individuals and 
in those who underwent skin prick testing with multiple 
fresh foods.
Anaphylactic reactions have been associated with 
monoclonal antibodies and biological modifiers and risk 
of anaphylaxis with omalizumab is reported to be 0.2 % 
(Järvinen and Celestin 2014). In our study, the risk of 
anaphylaxis development with the administration of 
omalizumab was found to be 0.21 %, and that was a HA. 
In the literature, a severe anaphylaxis with hypertension 
after applying oxaliplatin (alkylating chemotherapeutic 
agent) was reported in two cases (Lee et al. 2007).
We assume that in minority of patients, early compen-
satory vasopressor response may be dominant, which 
can cause anaphylactic reactions manifesting with hyper-
tensive attacks. Especially, in young patients, the possi-
bility of a hypertensive attack in anaphylactic reactions 
should be kept in mind, and the arterial blood pressure 
should be measured prior to the epinephrine injection 
to avoid a potential dangerous side effect of epinephrine 
(Wendt et al. 2011). There is no information in the litera-
ture regarding rates of hypertensive anaphylactic reac-
tions. We think that this is due to insufficient evidence of 
hypertension during the course of an acute anaphylactic 
reaction which is also perplexed by prompt administra-
tion of epinephrine in order to prevent potential life-
threatening reactions like upper airway obstruction.
In conclusion, even though a hypertensive attack may 
occur in few of anaphylaxis patients, there must be no 
hesitation for using epinephrine during the potential life-
threatening manifestations of anaphylaxis, such as upper 
airway obstruction. Anaphylaxis and hypertension can 
be recovered by epinephrine injection when required. 
According to the best of our knowledge, this study is the 
first original study about the prevalence of HA in Eng-
lish-medical literature.
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